Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.72 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.54 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121689 | 0.91 | SCN9A (0.72) | SCN9ASCN5ADGAT2S1PR1 | |
| SCHEMBL2130522 | 0.87 | SCN9A (0.71) | SCN9ASCN5ADGAT2KDM4E | |
| SCHEMBL19510382 | 0.84 | SCN9A (1.00) | SCN9ASCN5A | |
| SCHEMBL122571 | 0.82 | SCN9A (0.67) | SCN9ASCN5AS1PR1 | |
| SCHEMBL121898 | 0.82 | SCN9A (0.51) | SCN9ASCN5ADGAT2KDM4E | |
| SCHEMBL121418 | 0.77 | IDO1 (0.58) | SCN9ASCN5AKDM4E | |
| SCHEMBL121389 | 0.77 | SCN9A (0.70) | SCN9ASCN5AS1PR1 | |
| SCHEMBL912468 | 0.76 | SCN9A (0.54) | SCN9ASCN5A | |
| SCHEMBL121883 | 0.75 | ASH1L (0.51) | SCN9A | |
| SCHEMBL2129782 | 0.74 | SCN9A (0.54) | SCN9ASCN5ADGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748417-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-06-10 | — | — | US | disclosed |
| US-8575363-B2 | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | disclosed |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196970-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | SCN9A 229/4885SCN5A 1231/4885DGAT2 53/4885 |
| US-20120101081-A1 | AMINO-PYRROLIDINE-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | SCN9A 229/4885SCN5A 1231/4885DGAT2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.